

1652
#10

Serial Number: 09/117,380B

ENTERED

RECEIVED
AUG 02 2000
THORNTON

- ☐ Changed a file from non-ASCII to ASCII
- ☐ Changed the margins in cases where the sequence text was "wrapped" down to the next line.
- ☐ Edited a format error in the Current Application Data section, specifically:
- ☐ Edited the Current Application Data section with the actual current number. The number inputted by the applicant was ☐ the prior application data; or ☐ other
- ☐ Added the mandatory heading and subheadings for "Current Application Data".
- ☐ Edited the "Number of Sequences" field. The applicant spelled out a number instead of using an integer.
- ☐ Changed the spelling of a mandatory field (the headings or subheadings), specifically:
- ☐ Corrected the SEQ ID NO when obviously incorrect. The sequence numbers that were edited were:
- ☐ Inserted or corrected a nucleic number at the end of a nucleic line. SEQ ID NO's edited:
- ☐ Corrected subheading placement. All responses must be on the same line as each subheading. If the applicant placed a response below the subheading, this was moved to its appropriate place.
- ☐ Inserted colons after headings/subheadings. Headings edited included:
- ☐ Deleted extra, invalid, headings used by an applicant, specifically:
- ☒ Deleted: ☒ non-ASCII "garbage" at the beginning/end of files; ☐ secretary initials/filename at end of file; ☐ page numbers throughout text; ☐ other invalid text, such as
- ☐ Inserted mandatory headings, specifically:
- ☐ Corrected an obvious error in the response, specifically:
- ☐ Edited identifiers where upper case is used but lower case is required, or vice versa.
- ☐ Corrected an error in the Number of Sequences field, specifically:
- ☐ A "Hard Page Break" code was inserted by the applicant. All occurrences had to be deleted.
- ☐ Deleted **ending** stop codon in amino acid sequences and adjusted the "(A)Length:" field accordingly (error due to a PatentIn bug). Sequences corrected:
- ☐ Other:

*Examiner: The above corrections must be communicated to the applicant in the first Office Action. DO NOT send a copy of this form.

1652

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/117,380B

DATE: 07/25/2000
TIME: 13:16:53

Input Set : A:\Pto.amc
Output Set: N:\CRF3\07252000\I117380B.raw

3 <110> APPLICANT: FRIDKIN, Matityahu
4 YAVIN, Eran J.
6 <120> TITLE OF INVENTION: ANTI-INFLAMMATORY PEPTIDES DERIVED FROM C-REACTIVE
7 PROTEIN
9 <130> FILE REFERENCE: FRIDKIN=1
11 <140> CURRENT APPLICATION NUMBER: 09/117,380B
12 <141> CURRENT FILING DATE: 1999-01-27
14 <150> PRIOR APPLICATION NUMBER: PCT/IL97/00032
15 <151> PRIOR FILING DATE: 1997-01-27
17 <150> PRIOR APPLICATION NUMBER: IL 116976
18 <151> PRIOR FILING DATE: 1996-01-31
20 <160> NUMBER OF SEQ ID NOS: 20
22 <170> SOFTWARE: PatentIn Ver. 2.0
24 <210> SEQ ID NO: 1
25 <211> LENGTH: 4
26 <212> TYPE: PRT
27 <213> ORGANISM: Artificial Sequence
29 <220> FEATURE:
30 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
32 <220> FEATURE:
33 <223> OTHER INFORMATION: The N-terminal Ala residue is modified with a
34 methoxysuccinyl group; the C-terminal Val residue
35 is modified with a nitroanilide group.
37 <400> SEQUENCE: 1
38 Ala Ala Pro Val
39 1
42 <210> SEQ ID NO: 2
43 <211> LENGTH: 4
44 <212> TYPE: PRT
45 <213> ORGANISM: Artificial Sequence
47 <220> FEATURE:
48 <223> OTHER INFORMATION: The N-terminal Ala residue is modified with a
49 succinyl group; the C-terminal Phe residue is
50 modified with a nitroanilide group.
52 <220> FEATURE:
53 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
55 <400> SEQUENCE: 2
56 Ala Ala Pro Phe
57 1
60 <210> SEQ ID NO: 3
61 <211> LENGTH: 206
62 <212> TYPE: PRT
63 <213> ORGANISM: Homo sapiens
65 <220> FEATURE:
66 <223> OTHER INFORMATION: The C-terminal Pro residue is modified with an OH group.
68 <400> SEQUENCE: 3
69 Glu Thr Asp Met Ser Arg Lys Ala Phe Val Phe Pro Lys Glu Ser Asp

RAW SEQUENCE LISTING
 PATENT APPLICATION: US/09/117,380B
 DATE: 07/25/2000
 TIME: 13:16:53

Input Set : A:\Pto.amc
 Output Set: N:\CRF3\07252000\1117380B.raw

```

70   1           5           10           15
72 Thr Ser Tyr Val Ser Leu Lys Ala Pro Leu Thr Lys Pro Leu Lys Ala
73                               20           25           30
75 Phe Thr Val Cys Leu His Phe Tyr Thr Glu Leu Ser Ser Thr Arg Gly
76                               35           40           45
78 Tyr Ser Ile Phe Ser Tyr Ala Thr Lys Arg Gln Asp Asn Glu Ile Leu
79                               50           55           60
81 Ile Phe Trp Ser Lys Asp Ile Gly Tyr Ser Phe Thr Val Gly Gly Ser
82 65           70           75           80
84 Glu Ile Leu Phe Glu Val Pro Glu Val Thr Val Ala Pro Val His Ile
85                               85           90           95
87 Cys Thr Ser Trp Glu Ser Ala Ser Gly Ile Val Glu Phe Trp Val Asp
88                               100          105          110
90 Gly Lys Pro Arg Val Arg Lys Ser Leu Lys Lys Gly Tyr Thr Val Gly
91                               115          120          125
93 Ala Glu Ala Ser Ile Ile Leu Gly Gln Glu Gln Asp Ser Phe Gly Gly
94                               130          135          140
96 Asn Phe Glu Gly Ser Gln Ser Leu Val Gly Asp Ile Gly Asn Val Asn
97 145          150          155          160
99 Met Trp Asp Phe Val Leu Ser Pro Asp Glu Ile Asn Thr Ile Tyr Leu
100          165          170          175
102 Gly Gly Pro Phe Ser Pro Asn Val Leu Asn Trp Arg Ala Leu Lys Tyr
103          180          185          190
105 Glu Val Gln Gly Glu Val Phe Thr Lys Pro Gln Leu Trp Pro
106          195          200          205
109 <210> SEQ ID NO: 4
110 <211> LENGTH: 28
111 <212> TYPE: PRT
112 <213> ORGANISM: Homo sapiens
114 <220> FEATURE:
115 <221> NAME/KEY: DISULFID
116 <222> LOCATION: (24)..(25)
118 <400> SEQUENCE: 4
119 Ser Phe Thr Val Gly Gly Ser Glu Ile Leu Phe Glu Val Pro Glu Val
120   1           5           10           15
122 Thr Val Ala Pro Val His Ile Cys Cys Leu His Phe
123           20           25
126 <210> SEQ ID NO: 5
127 <211> LENGTH: 28
128 <212> TYPE: PRT
129 <213> ORGANISM: Artificial Sequence
131 <220> FEATURE:
132 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
134 <400> SEQUENCE: 5
135 Thr Ile Asn Glu Lys Gly Thr Glu Ala Ala Gly Ala Met Phe Leu Glu
136   1           5           10           15
138 Ala Ile Pro Met Thr Ile Pro Pro Glu Val Lys Phe
139           20           25
142 <210> SEQ ID NO: 6

```

RAW SEQUENCE LISTING DATE: 07/25/2000
PATENT APPLICATION: US/09/117,380B TIME: 13:16:53

Input Set : A:\Pto.amc
Output Set: N:\CRF3\07252000\I117380B.raw

143 <211> LENGTH: 13
144 <212> TYPE: PRT
145 <213> ORGANISM: Artificial Sequence
147 <220> FEATURE:
148 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
150 <220> FEATURE:
151 <221> NAME/KEY: DISULFID
152 <222> LOCATION: (9)..(10)
154 <400> SEQUENCE: 6
155 Val Thr Val Ala Pro Val His Ile Cys Cys Leu His Phe
156 1 5 10
159 <210> SEQ ID NO: 7
160 <211> LENGTH: 23
161 <212> TYPE: PRT
162 <213> ORGANISM: Artificial Sequence
164 <220> FEATURE:
165 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
167 <400> SEQUENCE: 7
168 Gly Ser Glu Ile Leu Phe Glu Val Pro Glu Val Thr Val Ala Pro Val
169 1 5 10 15
171 His Ile Cys Cys His Leu Phe
172 20
175 <210> SEQ ID NO: 8
176 <211> LENGTH: 8
177 <212> TYPE: PRT
178 <213> ORGANISM: Artificial Sequence
180 <220> FEATURE:
181 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
183 <400> SEQUENCE: 8
184 Val Thr Val Ala Pro Val Ser Ile
185 1 5
188 <210> SEQ ID NO: 9
189 <211> LENGTH: 8
190 <212> TYPE: PRT
191 <213> ORGANISM: Artificial Sequence
193 <220> FEATURE:
194 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
196 <400> SEQUENCE: 9
197 Val Thr Val Ala Pro Val Phe Ile
198 1 5
201 <210> SEQ ID NO: 10
202 <211> LENGTH: 9
203 <212> TYPE: PRT
204 <213> ORGANISM: Artificial Sequence
206 <220> FEATURE:
207 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
209 <220> FEATURE:
210 <223> OTHER INFORMATION: The C-terminal Pro residue is modified with an
211 NH2 group

RECEIVED
AUG 02 2000
TECH CENTER 1600/2300

RAW SEQUENCE LISTING DATE: 07/25/2000
 PATENT APPLICATION: US/09/117,380B TIME: 13:16:53

Input Set : A:\Pto.amc
 Output Set: N:\CRF3\07252000\I117380B.raw

```

213 <400> SEQUENCE: 10
214 Val Thr Val Ala Pro Val His Ile Pro
215   1                               5
218 <210> SEQ ID NO: 11
219 <211> LENGTH: 9
220 <212> TYPE: PRT
221 <213> ORGANISM: Artificial Sequence
223 <220> FEATURE:
224 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
226 <220> FEATURE:
227 <223> OTHER INFORMATION: The C-terminal Pro residue is modified with an
228   NH2 group
230 <400> SEQUENCE: 11
231 Val Thr Val Ala Pro Phe His Ile Pro
232   1                               5
235 <210> SEQ ID NO: 12
236 <211> LENGTH: 10
237 <212> TYPE: PRT
238 <213> ORGANISM: Artificial Sequence
240 <220> FEATURE:
241 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
243 <220> FEATURE:
244 <223> OTHER INFORMATION: The C-terminal Pro residue is modified with an NH2
245   group
247 <400> SEQUENCE: 12
248 Val Thr Val Ala Pro Val His Ile Pro Pro
249   1                               5           10
252 <210> SEQ ID NO: 13
253 <211> LENGTH: 8
254 <212> TYPE: PRT
255 <213> ORGANISM: Artificial Sequence
257 <220> FEATURE:
258 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
260 <220> FEATURE:
261 <223> OTHER INFORMATION: The N-terminal Val residue may be modified with a
262   monomethoxy-succinyl group, a 1,adamantyl-NH-CO
263   group, an a-naphtyl-NH-CO group, an octanoyl group, a
264   carbobenzoxy protecting group, a 6-actylamino-N-hexanoyl
W--> 265   group, a 9-fluorenylmethoxycarbonly group, an H-group, a
W--> 266   CH3OCO(CH2)2CO group, a CH3(CH2)6CO group, or a CH3CONH(CH2)5CO
W--> 267   group.
W--> 269   The C-terminal Ile residue may be modified with an OH group
W--> 270   or an NH2 group,
272 <400> SEQUENCE: 13
273 Val Thr Val Ala Pro Val His Ile
274   1                               5
277 <210> SEQ ID NO: 14
278 <211> LENGTH: 9
279 <212> TYPE: PRT

```

RAW SEQUENCE LISTING DATE: 07/25/2000
 PATENT APPLICATION: US/09/117,380B TIME: 13:16:53

Input Set : A:\Pto.amc
 Output Set: N:\CRF3\07252000\I117380B.raw

```

280 <213> ORGANISM: Artificial Sequence
282 <220> FEATURE:
283 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
285 <220> FEATURE:
286 <223> OTHER INFORMATION: The N-terminal Phe residue may be modified with a
287 monomethoxy-succinyl group, a carbobenzoxy
288 protecting group, a CH3OCO(CH2)2C) group, or an H group
291 The C-terminal Ile residue may be modified with an OH
W--> 292 group or joined to a polymer
296 <400> SEQUENCE: 14
297 Phe Val Thr Val Ala Pro Val His Ile
298 1 5
301 <210> SEQ ID NO: 15
302 <211> LENGTH: 8
303 <212> TYPE: PRT
304 <213> ORGANISM: Artificial Sequence
306 <220> FEATURE:
307 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
309 <400> SEQUENCE: 15
310 Leu Glu Ala Ile Pro Met Ser Ile
311 1 5
314 <210> SEQ ID NO: 16
315 <211> LENGTH: 8
316 <212> TYPE: PRT
317 <213> ORGANISM: Artificial Sequence
319 <220> FEATURE:
320 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
322 <220> FEATURE:
323 <223> OTHER INFORMATION: Xaa at position 7 is 1,4-(L)diaminobutyric acid
325 <400> SEQUENCE: 16
W--> 326 Val Thr Val Ala Pro Val Xaa Ile
327 1 5
330 <210> SEQ ID NO: 17
331 <211> LENGTH: 8
332 <212> TYPE: PRT
333 <213> ORGANISM: Artificial Sequence
335 <220> FEATURE:
336 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
338 <220> FEATURE:
339 <223> OTHER INFORMATION: Xaa at position 5 is N-methyl glycine
341 <400> SEQUENCE: 17
W--> 342 Val Thr Val Ala Xaa Val His Ile
343 1 5
346 <210> SEQ ID NO: 18
347 <211> LENGTH: 9
348 <212> TYPE: PRT
349 <213> ORGANISM: Artificial Sequence
351 <220> FEATURE:
352 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic

```

VERIFICATION SUMMARY

DATE: 07/25/2000

PATENT APPLICATION: US/09/117,380B

TIME: 13:16:54

Input Set : A:\Pto.amc

Output Set: N:\CRF3\07252000\I117380B.raw

L:265 M:259 W: Field exceeds allowed number of lines, <223> Other Information:
L:266 M:259 W: Field exceeds allowed number of lines, <223> Other Information:
L:267 M:259 W: Field exceeds allowed number of lines, <223> Other Information:
L:269 M:259 W: Field exceeds allowed number of lines, <223> Other Information:
L:270 M:259 W: Field exceeds allowed number of lines, <223> Other Information:
L:292 M:259 W: Field exceeds allowed number of lines, <223> Other Information:
L:326 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:16
L:326 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:16
L:326 M:340 W: (46) "n" or "Xaa" used: Feature required, for SEQ ID#:16
L:342 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:17
L:342 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:17
L:342 M:340 W: (46) "n" or "Xaa" used: Feature required, for SEQ ID#:17
L:398 M:259 W: Field exceeds allowed number of lines, <223> Other Information:

1652

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/117,380B

DATE: 05/05/2000

TIME: 12:16:14

Input Set : A:\fridkin1.txt

Output Set: N:\CRF3\05052000\I117380.raw

*Does Not Comply
Corrected Diskette Needed*

3 <110> APPLICANT: FRIDKIN, Matityahu
 4 YAVIN, Eran J.
 6 <120> TITLE OF INVENTION: ANTI-INFLAMMATORY PEPTIDES DERIVED FROM C-REACTIVE
 7 PROTEIN
 9 <130> FILE REFERENCE: FRIDKIN=1
 11 <140> CURRENT APPLICATION NUMBER: 09/117,380
 12 <141> CURRENT FILING DATE: 1999-01-27
 14 <150> PRIOR APPLICATION NUMBER: PCT/IL97/00032
 15 <151> PRIOR FILING DATE: 1997-01-27
 17 <150> PRIOR APPLICATION NUMBER: IL 116976
 18 <151> PRIOR FILING DATE: 1996-01-31
 20 <160> NUMBER OF SEQ ID NOS: 20
 22 <170> SOFTWARE: PatentIn Ver. 2.0

ERRORED SEQUENCES

385 <210> SEQ ID NO: 20
 386 <211> LENGTH: 8
 387 <212> TYPE: PRT
 388 <213> ORGANISM: Artificial Sequence
 390 <220> FEATURE:
 391 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 393 <220> FEATURE:
 394 <223> OTHER INFORMATION: The N-terminal Val residue is modified with an H
 395 group; Thr at position 2 is modified with
 396 tert.-butyl-ether; His at position 7 is modified
 397 with trityl; and the C-terminal Ile residue is joined to a
 W--> 398 polymer
 400 <400> SEQUENCE: 20
 401 Val Thr Val Ala Pro Val His Ile
 402 1 5
 E--> 408 1

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/117,380^β

DATE: 05/05/2000

TIME: 12:16:15

Input Set : A:\fridkin1.txt

Output Set: N:\CRF3\05052000\I117380.raw

L:265 M:259 W: Field exceeds allowed number of lines, <223> Other Information:
L:266 M:259 W: Field exceeds allowed number of lines, <223> Other Information:
L:267 M:259 W: Field exceeds allowed number of lines, <223> Other Information:
L:269 M:259 W: Field exceeds allowed number of lines, <223> Other Information:
L:270 M:259 W: Field exceeds allowed number of lines, <223> Other Information:
L:292 M:259 W: Field exceeds allowed number of lines, <223> Other Information:
L:326 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:16
L:326 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:16
L:326 M:340 W: (46) "n" or "Xaa" used: Feature required, for SEQ ID#:16
L:342 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:17
L:342 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:17
L:342 M:340 W: (46) "n" or "Xaa" used: Feature-required, for SEQ ID#:17
L:398 M:259 W: Field exceeds allowed number of lines, <223> Other Information:
L:408 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:20